Modulating Inflammatory and Fibrogenic Pathways in Kidney Disease using a novel antagonist of Protease-Activated-Receptor-2

使用蛋白酶激活受体 2 的新型拮抗剂调节肾脏疾病的炎症和纤维化途径

• 批准号: nhmrc : 1083131
• 负责人: A/Pr David Nikolic-Paterson
• 金额: $ 39.89万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/modulating-inflammatory-fibrogenic-receptor-2/518914
• 关键词: Modulating; Inflammatory; Fibrogenic; Pathways; Kidney

Chronic kidney disease (CKD) now affects 10% of adults in industrialised countries. Current treatments are largely ineffective. Thus developing better CKD treatments will have substantial public health benefit. Three well established and clinically relevant animal models of kidney disease will be used to test the ability of a new experimental anti-inflammatory drug, developed by members of this research team at The University of Queensland, to prevent or lessen the progression of CKD.

目前，慢性肾病 (CKD) 影响着工业化国家 10% 的成年人。目前的治疗基本上无效。因此，开发更好的 CKD 治疗方法将为公众健康带来巨大益处。昆士兰大学研究小组成员开发的一种新的实验性抗炎药物将使用三种成熟且具有临床相关性的肾脏疾病动物模型来测试其预防或减轻 CKD 进展的能力。